**Table S2. Patient characteristics (A) and 2DLC-MS/MS analysis (B).**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **A** | **Code\*** | **Age** | **Sex** | **D4Z4 units** | **Muscle type (Brooke-Vignos scale)** | **Predominantly FSHD myotube phenotype (MFI %)** |
|  | **aFSHD3** | 32 | F | 7 | Q(1-1) | Atrophic (37) |
|  | **dFSHD12** | 38 | F | 7 | Q(1-1) | Disorganized (60) |
|  | **a/dFSHD8** | 39 | M | 6 | Q(2-1) | Atrophic/Disorganized (53) |
|  | **CTL7** | 46 | M | ND | Q |  |
|  | **CTL12** | 35 | F | ND | Q |  |

\*myoblasts previously characterized in Barro *et al.,* 2010

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **B** | **Analysis code** | **Myoblast lines** | **Differentiation stages** | **Protein extracts** | **ICPL methods** | **2DLC (SCX column types)** | **Number of identified proteins** | **Number of quantified proteins** | **Number of identified peptides** |
|  | **#P1** | a/dFSHD8 vs CTL7 | d6 | TE | Regular | P | 145 | 61 | 173 |
|  | **#P2** | dFSHD12 | d4 | TE | X | B | 518 | X | 1855 |
|  | **#P3** | dFSHD12 | d4 | NE | X | B | 648 | X | 3222 |
|  | **#dFSHD12\_TE** | dFSHD12 vs CTL12 | d4 | TE | Post-digest | B | 268 | 195 | 1171 |
|  | **#dFSHD12\_NE** | dFSHD12 vs CTL12 | d4 | NE | Post-digest | B | 292 | 215 | 939 |
|  | **#aFSHD3\_TE** | aFSHD3 vs CTL12 | d4 | TE | Post-digest | B | 207 | 151 | 1302 |
|  | **#aFSHD3\_NE** | aFSHD3 vs CTL12 | d4 | NE | Post-digest | B | 149 | 122 | 711 |